Clin2
NCT06885697Possibly a fitRecruiting

CAR T cells targeting mesothelin for solid tumors

MesotheliomaNeoplasmsStomach NeoplasmsPancreatic NeoplasmsOvarian NeoplasmsLung NeoplasmsThymus NeoplasmsColonic Neoplasms

Treatments studied

Part of Blood & lymphatic, Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.

This study tests a new treatment called CAR T cells that target a protein called mesothelin found on certain cancer cells. The CAR T cells are made from your own immune cells and may help shrink tumors that have not responded to other therapies.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
100 people
Ages
18 years to 120 years
Study type
Interventional

Who can take part

  • You have a type of cancer called mesothelioma (with certain cell types) or another solid tumor that makes the mesothelin protein.
  • Your cancer has grown after at least one standard treatment, or you have pancreatic cancer and can collect cells before starting treatment.
  • You are 18 years or older and in good daily health (ECOG 0 or 1).
  • Your blood counts, liver, kidney, and heart function are within study limits.
  • You do not have uncontrolled autoimmune disease, lung scarring, or active infections like HIV or hepatitis.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06051695Recruiting· Phase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors

This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.

Gilbert, Arizona
NCT06196294Recruiting· Phase 1
Engineered immune cells for cancers with GPC3 or mesothelin

This trial tests a new type of immune cell therapy made from your own cells (gamma-delta T cells) that are engineered to find and attack cancers that have GPC3 or mesothelin proteins. It may be an option for people with advanced cancer who have not had gene therapy before and are in generally good health.

Guangzhou, Guangdong
NCT07420010Not yet recruiting· Early Phase 1
KT032 cell therapy for mesothelin-positive advanced tumors

This trial tests a new treatment called KT032, which are special immune cells (CAR-T cells) designed to attack cancer cells that have a protein called mesothelin. It is for people with advanced solid tumors, especially those that have spread to the abdomen, who have run out of standard options.

NCT05783089Not yet recruiting· Phase 1
CAR-T cell therapy for mesothelin-positive solid cancers

This Phase 1 trial tests a lab-made immune therapy (anti-mesothelin CAR-T) for adults with solid tumors that have come back or did not respond to standard treatment. It targets cancers that are mesothelin-positive in tumor testing and aims to see if the treatment is safe and can work.

NCT06623396Recruiting· Phase 1
CAR T-cell therapy for stomach and esophagus cancer

This trial tests a new treatment called CAR T-cell therapy that targets a protein called mesothelin found on some cancer cells. It is for people with advanced or recurrent cancer of the stomach or esophagus that has spread or come back after prior treatment.

Basking Ridge, New Jersey
NCT05779917Recruiting· Phase 1
CAR-T cells for cancers that have specific target proteins

This Phase 1 trial tests a customized immune therapy (CAR-T cells) for advanced cancers that have the proteins mesothelin, GPC3, and/or GUCY2C. It may help your body better recognize and kill cancer cells, but early-phase trials mainly focus on safety and learning how well the treatment works.

Guangzhou, Guangdong

Hear when a new Mesothelioma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.